News
Resources
Blog
Sites
Holly Campbell Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.
Recent Posts
Study finds hospitals continue to mark up medicines up to 500% of their cost
By Holly Campbell | July 9, 2019
A new analysis from the Moran Company found hospitals continue to charge, on average, five times their cost for medicines, driving up cost sharing and premiums for patients across the country....
Read More
Three reasons why the latest Rx Savings Solutions analysis is misleading
By Holly Campbell | July 2, 2019
Yesterday, multiple news outlets featured data from Rx Savings Solutions on medicine price trends. These data reflect list price increases, ignoring the significant rebates and discounts on...
Read More
86 percent of AARP members support the Medicare rebate rule that AARP opposes
By Holly Campbell | June 12, 2019
Eighty-six percent of AARP members support the administration’s proposed rule to reform the rebate system in Medicare Part D, according to a nationwide Morning Consult survey commissioned by the...
Read More
New report finds 15 new oncology therapies launched last year
By Holly Campbell | June 5, 2019
A record 15 new oncology therapeutics launched in 2018 for 17 tumor types, according to IQVIA’s “Global Oncology Trends 2019” report. This progress includes a continued shift toward precision...
Read More
New study finds hospitals continue to push patients to costlier outpatient settings
By Holly Campbell | May 13, 2019
A new study from the Health Care Cost Institute found that, for commercially insured patients, almost 50 percent of medicines administered by physicians, including treatments for diseases like...
Read More
Today, IQVIA released its Medicine Use and Spending in the U.S. – A Review of 2018 and Outlook to 2023 report – highlighting the drivers behind medicine price and spending trends, patient...
Read More
Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”
By Holly Campbell | May 9, 2019
Reinforcing our industry’s commitment to providing patients with more transparency about medicine costs, yesterday, our member companies announced the launch of the Medicine Assistance Tool, or MAT
Read More
Six policy solutions to help patients afford their insulin
By Holly Campbell | April 9, 2019
Updated on 08/12/2019 Dramatic improvements in how we treat diabetes have transformed the lives of patients, but too many struggle to afford their insulin and other medicines at the pharmacy...
Read More
PhRMA comments on OIG proposed rule to reform the rebate system
By Holly Campbell | April 8, 2019
Today, PhRMA submitted comments on the Department of Health & Human Services (HHS) Office of Inspector General (OIG) proposed rule, “Removal of Safe Harbor Protection for Rebates Involving...
Read More
Five key facts about the market for insulins
By Holly Campbell | April 1, 2019
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
